tirzepatide 2022 vs. Retatrutide: Key Differences Explained What To Know About Tirzepatide

Santocono M, Zurria M, Berrettini M, Fedeli D, Falcioni G

As shown by the images, baseline BMIs were quite high (~3738 kg/m 2 , Class II obesity) and, as depicted by the avatars, body size and shape remained in the overweight-obese range following 72 weeks of medication treatment

N., Vieta, E., & Malhi, G

Importantly, SANA was also detectable in several tissues including inguinal white adipose tissue (iWAT

doi: 10.3390/nu15112587

Here's what we'll cover Here's what we'll cover Here's what we'll cover Key takeaways Zepbound (tirzepatide) has not been well studied during breastfeeding, so it is important to talk with a healthcare provider before using it while nursing